(Q36191044)

12 August 2017

1 reference

title

A review of clozapine safety (English)

1 reference

12 August 2017

2

1 reference

12 August 2017

4

Michel Bourin

1 reference

12 August 2017

Joanna Fitzsimons

1

1 reference

12 August 2017

Timothy Lambert

series ordinal

3

1 reference

12 August 2017

Seetal Dodd

series ordinal

5

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

731-744

1 reference

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clinical profile of clozapine: adverse reactions and agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine maintenance therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Eosinophilia after commencement of clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Effects of antipsychotic drugs on cytokine networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Effects of clozapine on plasma cytokine and soluble cytokine receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

The characteristics of clozapine-induced fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Bacterial pneumonia can increase serum concentration of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Deaths of psychiatric patients during heat waves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Update on the clinical efficacy and side effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Antipsychotic medication and seizures: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine-related seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

21 January 2018

Clozapine and seizures

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Carbamazepine withdrawal: effects of taper rate on seizure frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Pharmacokinetics and pharmacodynamics of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Polypharmacy in fatal clozapine-associated agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Myoclonic epileptic seizures during clozapine treatment: a report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Delirium during clozapine treatment: incidence and associated risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Cross-cultural structures of concentric and diametric dualism in Lévi-Strauss' structural anthropology: structures of relation underlying the self and ego relation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Branded versus generic clozapine for treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Treatment of clozapine sedation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Obsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Can clozapine trigger OCD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Myocarditis and cardiomyopathy associated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Myocarditis and cardiomyopathy associated with clozapine use in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine associated dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Physical consequences of schizophrenia and its treatment: the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Association of venous thromboembolism and clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Weight changes during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Bodyweight gain with atypical antipsychotics. A comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine's effects on body weight and resting metabolic rate: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

New-onset diabetes and ketoacidosis with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Deaths from diabetic ketoacidosis after long-term clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine-associated extrapyramidal reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Extrapyramidal side effects of clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clinical management of neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Neuroleptic malignant syndrome: review and analysis of 115 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine-induced hypersalivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Reversal by physostigmine of clozapine-induced delirium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Antipsychotics: impact on prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Hepatotoxicity of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.731

21 January 2018

Identifiers

DOI

10.1517/14740338.4.4.731

1 reference

12 August 2017

1 reference